TEL AVIV, Israel: Company unveils breakthrough platform that integrates epiproteomics and AI to identify predictive biomarkers for personalized treatments and support drug development TEL AVIV, Israel, Dec. 16, 2024 /PRNewswire/ — Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment. This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.